RTA

Investigational multi-receptor peptide agonist (retatrutide, LY3437943) that interacts with the GLP-1, GIP, and glucagon receptor families. Studied for its ability to modulate multiple metabolic pathways simultaneously, allowing researchers to explore combined incretin-glucagon signaling mechanisms. Because it engages three receptor systems involved in glucose regulation, lipid metabolism, energy balance, and gastrointestinal signaling, RTA provides a model for evaluating how coordinated receptor activation may influence metabolic processes.

Sold exclusively to licensed medical and clinical B2B accounts. Intended for professional use under the supervision of licensed practitioners.